Endometrial carcinoma: treatment  by unknown
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DESCRIPTION OF THE EVIDENCE COLLECTION METHOD
The bibliographic review of scientiﬁc articles was 
performed in the databases EMBASE, SciELO/LILACS, 
PubMed/Medline, and the Cochrane Library using the 
keywords (MeSH terms) grouped as follows: (endometrial 
neoplasm OR carcinoma, endometrial OR endometrial 
cancers OR endometrium cancer OR uterine neoplasm 
OR neoplasm, uterus OR uterus cancers OR cancer of 
the uterus OR uterine cancers) AND adenocarcinoma 
AND risk factors AND (neoplasm staging OR tumor 
staging OR cancer staging) AND neoplasm invasiveness 
AND neoplasm metastasis AND lymphatic metastasis 
AND (antineoplastic agent, hormonal OR hormonal 
antineoplastic drugs) AND medroxyprogesterone AND 
tamoxifen AND (neoplasm recurrence, local OR local 
neoplasm recurrence) AND recurrence AND (lymph node 
excision OR lymph node dissections OR node dissection, 
lymph) AND (adjuvant chemotherapy OR chemotherapy, 
adjuvant) AND (antineoplastic combined chemotherapy 
protocols OR antineoplastic agents, combined OR cancer 
chemotherapy protocol) AND (adjuvant radiotherapy OR 
radiotherapy, adjuvant) AND radiotherapy, high-energy 
AND combined modality therapy AND (laparoscopy 
OR surgical procedures, laparoscopic OR laparoscopic 
surgery OR laparoscopic surgical procedures) AND 
laparotomy AND postoperative complications AND 
follow-up studies.
DEGREE OF RECOMMENDATION AND STRENGTH OF EVIDENCE:
A: Experimental or observational studies of higher 
consistency.
B: Experimental or observational studies of lesser 
consistency.
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OBJECTIVE 
To evaluate the main approaches in the treatment of en-
dometrial carcinoma according to the available evidence.
INTRODUCTION
Endometrial cancer is one of the most common malignant 
neoplasms of the female genital tract in Western Europe 
and North America1,2 (D). 
More than 90% of cases occur in women older than 
50 years (mean age 63 years), contributing to 1% to 2% of 
all causes of death by cancer. The most common symptom 
is vaginal bleeding and when diagnosed soon after symp-
toms onset, the disease is limited to the uterus in more 
than 75% of patients, therefore in its early stages, with fa-
vorable prognosis and high rates of overall survival (80% 
to 85%) in five years3 (D).
The International Federation of Gynecology and Ob-
stetrics (FIGO) introduced in 1988 and updated in 2009 
the staging system for endometrial cancer, which is sur-
gical-pathological and defined after total abdominal hys-
terectomy, bilateral salpingo-oophorectomy, pelvic and 
periaortic lymphadenectomy, and peritoneal cytology; 
the prognosis depends on age, histology and tumor grade, 
depth of invasion in the myometrium, cervical involve-
ment, and lymph node metastasis4,5(B)6(C)7(D).
1. DOES THE USE OF ADJUVANT ENDOCRINE THERAPY 
IN PATIENTS WITH ENDOMETRIAL CARCINOMA RESULT IN 
OVERALL SURVIVAL IMPROVEMENT?
The primary treatment of endometrial carcinoma, main-
ly represented by surgery and radiotherapy, especially in 
cases of undifferentiated tumors with deep myometrial 
infiltration, does not show favorable results in tumor con-
trol. As endometrial carcinoma is a hormone-dependent 
disease, the hypothesis that the use of adjuvant endocrine 
therapy might result in improvement has been supported, 
preventing recurrence and death in patients with the dis-
ease at early stages8-11(A).
In a prospective study, evaluating women with a mean 
age of 63 years submitted to surgical therapy (abdominal 
hysterectomy, bilateral salpingo-oophorectomy, and par-
tial colpectomy) with histological diagnosis of endome-
trial carcinoma stage I or II (FIGO), of which 57% were 
C: Case reports (non-controlled studies).
D: Opinion without critical evaluation, based on con-
sensuses, physiological studies or animal models.
 Este é um artigo Open Access sob a licença de CC BY-NC-ND
GUIDELINES IN FOCUS
282 Rev Assoc Med Bras 2012; 58(3):281-286
stage IB and subsequently submitted to adjuvant endo-
crine therapy with the use of medroxyprogesterone acetate 
(MPA) at a dose of 500 mg/day or tamoxifen 30 mg/day 
for a mean period of 56 months, overall survival was simi-
lar in both treatment groups when compared with con-
trol group, ARR = 0.001 with 95% CI (-0.090-0.092) and 
ARR = -0.023  with 95% CI (-0.001-0.163) for the MPA 
and tamoxifen, respectively12(B).
Regarding the adverse effects, they occurred more 
frequently in users of MPA and tamoxifen (59% and 49% 
respectively), with deterioration of glycemic control and 
peripheral edema more often observed with the use of 
MPA12 (B).
RECOMMENDATION
In patients with early-stage endometrial carcinoma, there 
is no indication for the use of adjuvant endocrine therapy.
2. IS THE PERFORMANCE OF A PELVIC LYMPHADENECTOMY 
IN PATIENTS WITH EARLY-STAGE ENDOMETRIAL CARCINOMA 
RELATED TO BETTER RESULTS REGARDING OVERALL SURVIVAL 
AND RECURRENCE? 
Endometrial carcinoma most frequently develops in the 
posterior wall and fundus of the uterus, spreads continu-
ously through the uterine body by myometrial invasion 
and cervical involvement, and has as its most frequent 
site of metastasis the retroperitoneal lymph nodes (pelvic 
lymph nodes), and less frequently, the periaortic lymph 
nodes. Patients with early-stage endometrial carcinoma 
(stage I) have metastasis in the pelvic lymph nodes at a 
frequency of approximately 10%.  
Considering the same staging technique, patients with 
superficial myometrial invasion by well-differentiated tu-
mor present lymph node involvement in about 3% to 5% 
of cases, and this proportion increases to 20% in poorly 
differentiated tumors and deep myometrial invasion. It is 
also known that in cases of retroperitoneal lymph node 
involvement of both pelvic and periaortic lymph nodes, 
the prognosis for five-year survival is compromised, with 
variable rates of 44% to 52%13(D). Thus, tumor grade, 
depth of invasion, and tumor type were prognostic fac-
tors of paramount importance, used to predict the pos-
sibility of recurrence as well as the need for the use of 
adjuvant therapy. 
Since 1988, when FIGO introduced the need for 
lymphadenectomy for the staging of endometrial cancer, 
many questions have been raised,  mainly regarding the 
extent of lymphadenectomy, indications, risks, and ben-
efits related to overall survival and recurrence.
Although some retrospective studies have shown an 
association between lymphadenectomy and improve-
ment in survival rates, others with high strength of evi-
dence are not in agreement with these results14,15(B). 
A multicenter randomized trial that evaluated patients 
with a mean age of 62 years and histological diagnosis 
of endometrial carcinoma limited to the uterine corpus 
(FIGO stage I) submitted to standard surgical procedure 
(total abdominal hysterectomy with bilateral salpingo-
oophorectomy) associated or not with systematic pelvic 
lymphadenectomy and mean follow-up of 49 months 
showed no influence of the performance of the lymphad-
enectomy in both the number of recurrences (12.9% ver-
sus 13.2% respectively), and overall survival. There was 
also a larger number of metastases in lymph nodes and 
staging changes (13.3% versus 3.2% of stage IIIC) with 
or without the performance of the lymphadenectomy, 
respectively16(A).
 Similar results were found in another random-
ized study, where during the mean follow-up of 37 months, 
women with early-stage endometrial carcinoma submitted 
primarily to standard surgical therapy (total abdominal 
hysterectomy with bilateral salpingo-oophorectomy) with 
or without lymphadenectomy, showed no clear benefits in 
terms of survival17(A).
RECOMMENDATION
In patients diagnosed with early-stage endometrial carci-
noma, the performance of pelvic lymphadenectomy asso-
ciated with standard surgery (total hysterectomy and bi-
lateral salpingo-oophorectomy), allows for the attainment 
of a more appropriate staging, by increasing the detection 
of lymph node metastases. It does not show, however, im-
provement in overall survival or reduction in the recur-
rence rate. 
3. DOES THE INDICATION FOR ADJUVANT PELVIC 
RADIOTHERAPY IN SURGICALLY-TREATED PATIENTS WITH 
EARLY-STAGE ENDOMETRIAL CARCINOMA DETERMINE 
IMPROVEMENT IN THE CONTROL OF LOCOREGIONAL 
RECURRENCES? 
As mentioned before, the most significant prognostic fac-
tors in endometrial carcinoma are the stage, histological 
grade, and depth of myometrial invasion. Other factors are 
the patient’s age, tumor histological type, peritoneal cytol-
ogy, progesterone receptor activity, and uterine size18,19(B). 
In the presence of high-risk factors for recurrence, such as 
myometrial invasion ≥ 50% or histological grades 2 or 3, 
pelvic radiotherapy is indicated. In a retrospective analy-
sis, patients with stage I endometrial carcinoma treated 
surgically and submitted to adjuvant radiotherapy showed 
overall survival rates in five years ranging from 80% to 
95%, and locoregional recurrence rates of approximately 
4% to 8% 20(A)21(B).
In a prospective, randomized study evaluating women 
with a mean age of 66 years, with stage I endometrial carci-
noma, histological grade 1, and myometrial invasion ≥ 50%; 
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or histological grade 2 with any degree of invasion; or 
histologic grade 3 with invasion < 50%; submitted or not 
to adjuvant pelvic radiotherapy totaling 46 Gy total dose, 
it was observed during a mean follow-up of 52 months, 
that locoregional recurrences are more often diagnosed 
in patients not treated with radiotherapy (14% versus 
4% respectively with ARR = 0.080 and 95% CI: 0.043-
0.117), with most recurrences limited to the vagina. Re-
garding overall survival, no significant difference is ob-
served between patients undergoing radiotherapy or not 
(ARR = -0.028 95%CI: 0.080-0.024). Regarding adverse 
events, it was observed that late complications are more 
frequent in patients undergoing adjuvant radiotherapy 
(25% versus 6% respectively, with p < 0.001), representing 
1/3 of the severe complications22(A).
When expanding the assessment to a period of 97 
months, a continued reduction in locoregional recurrence 
in patients undergoing adjuvant radiotherapy was ob-
served (5% versus 14% respectively, with p < 0.0001)23(B).
RECOMMENDATION
The use of adjuvant radiotherapy in patients with early-
stage endometrial carcinoma showed a reduction in lo-
coregional recurrences but no influence on survival. Due 
to the adverse events related to the use of adjuvant radio-
therapy, this should not be the treatment of choice to pre-
vent local recurrence only, and therefore, it is not recom-
mended for early-stage carcinomas in the absence of risk 
factors for metastases.
4. IS LAPAROSCOPIC SURGERY SAFE AND EFFECTIVE IN THE 
TREATMENT OF ENDOMETRIAL CARCINOMA?
The standard approach for the treatment and staging of 
endometrial carcinoma consists of total abdominal hys-
terectomy, bilateral salpingo-oophorectomy, periaortic 
and pelvic lymphadenectomy, and peritoneal lavage4(D). 
However, in recent years, there has been a growing inter-
est in surgical techniques for the treatment of gyneco-
logical malignancies, particularly laparoscopic surgery, 
in the treatment of endometrial carcinoma24(B)25(C). 
Compared with laparotomy, the laparoscopic surgery has 
advantages such as smaller incisions, better visibility of 
the surgical field, less blood loss, less postoperative pain, 
faster postoperative recovery with shorter hospitaliza-
tion, and faster return to usual activities, with no surgical 
limitations for obese and older patients26-29(B).
Regarding the overall survival and number of re-
currences, prospective and retrospective studies have 
shown no significant difference between the laparo-
scopic and laparotomy techniques for the treatment of 
patients with early-stage endometrial carcinoma30,31(B). 
The same can be observed with respect to intraoperative 
complications32(B).
In a prospective randomized study that assessed wom-
en with early-stage endometrial carcinoma (stage I) sub-
mitted to laparotomy or laparoscopy, and a mean follow-
up of 38 months, no significant differences were observed 
in both the number of recurrences between the two ap-
proaches (11.5% versus 8.6% respectively) and intraopera-
tive complications33(A). Another prospective study of pa-
tients with early-stage endometrial carcinoma treated by 
laparoscopy or laparotomy had a longer follow-up of seven 
years, aiming at evaluating recurrences and no significant 
difference was observed between the two procedures 
(20% versus 18.4% respectively, with p = 0.860)34(A).
RECOMMENDATION
Although the laparoscopic approach is not the standard 
treatment for endometrial carcinoma, when performed by 
trained professionals it has shown to be a safe and effective 
alternative for the treatment of early-stage endometrial 
carcinoma without compromising the required oncologi-
cal stringency. 
5. DOES THE USE OF ADJUVANT CHEMOTHERAPY IN PATIENTS 
WITH HIGH-RISK ENDOMETRIAL CARCINOMA (STAGES IB G3, 
II G3 WITH MYOMETRIAL INVASION > 50%, AND STAGE III) 
DEMONSTRATE BENEFITS IN TERMS OF OVERALL SURVIVAL 
WHEN COMPARED TO PELVIC RADIOTHERAPY? 
Approximately 10% to 15% of patients with early-stage en-
dometrial carcinoma will have disease recurrence22(A)35(B). 
Thus, both chemotherapy and radiation therapy have been 
used aiming at the reduction in recurrence rate. However, 
the best therapeutic approach remains controversial. Ran-
domized trials assessing adjuvant radiotherapy for early-
stage endometrial carcinoma have shown a significant 
reduction in locoregional recurrences, but no influence 
on survival22(A). As a result, studies using chemotherapy 
and/or radiotherapy as adjuvant treatments have been de-
veloped in an attempt to improve survival. 
In a multicenter randomized study, patients with 
a mean age of 59 years who had endometrial carci-
noma stages IC (61%) to IIIC (11.9%) with myometrial 
invasion > 50%, originally submitted to total abdominal 
hysterectomy, bilateral salpingo-oophorectomy, and pel-
vic and periaortic lymphadenectomy (performed in 96% 
and 28% of patients, respectively) were evaluated. After 
the surgical procedure, pelvic radiotherapy at a dose of 
45-50 Gy and a CAP chemotherapy regimen (cyclophos-
phamide, doxorubicin, and cisplatin) was used. There 
was no significant difference in both the number of re-
currences (both intra and extra-pelvic) between the two 
approaches (ARR = -0.006 95% CI: -0.057-0.045, and 
ARR = -0.026 95% CI: -0.097-0.045 respectively) and over-
all survival (ARR = -0.036 95% CI: -0.108-0.036) after 59 
months of follow-up36(A). Another randomized study, 
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using the same chemotherapy and radiotherapy regimen 
in patients with high-risk endometrial carcinoma, also 
failed to demonstrate, during the evaluation period of 
95 months, any difference between treatments regarding 
the increase in disease-free survival and overall survival 
(ARR = 0.039 95% CI: -0.062-0.140, and ARR = -0.003 
95% CI: -0.052-0.046, respectively)37(B).
RECOMMENDATION
Both chemotherapy and adjuvant pelvic radiotherapy 
in patients with high-risk endometrial carcinoma dem-
onstrate no significant difference regarding overall sur-
vival.
6. DOES THE USE OF CHEMOTHERAPY ASSOCIATED WITH 
RADIOTHERAPY INDICATED IN THE TREATMENT OF HIGH-
RISK ENDOMETRIAL CARCINOMA SHOW BETTER RESULTS 
IN TERMS OF DISTANT METASTASES WHEN COMPARED TO 
RADIOTHERAPY ALONE?
The myometrial invasion, histological tumor grade, and 
presence of extrauterine disease are associated with high 
incidence of cervical and adnexal involvement and me-
tastasis to retroperitoneal lymph nodes4,38(B)39(C). Ad-
juvant radiotherapy used in high-risk endometrial car-
cinoma (myometrial and cervical invasion and advanced 
histological grade) has shown consistent results in reduc-
tion of locoregional recurrence but without modifying 
distant involvement, a factor that interferes with survival 
rates22(A). Thus, the combination of radiation therapy 
and chemotherapy began to be evaluated in order to in-
crease overall survival. 
When evaluating patients with a mean age of 74 years, 
with stages IA-B endometrial carcinoma and histologi-
cal grade 3 or stages IC-IIIA with histological grades 1-3, 
originally submitted to total abdominal hysterectomy, bi-
lateral salpingo-oophorectomy, and pelvic lymphadenec-
tomy performed in 80% of the patients, and after pelvic 
radiotherapy (total dose of 56 Gy) or pelvic radiotherapy 
associated with chemotherapy consisting of three cycles 
of 50 mg/m2 cisplatin, 60 mg/m2 of epirubicin, and 500 
mg/m2 of cyclophosphamide; after a follow-up of five 
years, it was observed that the combined regimen was 
not able to prevent the occurrence of distant metastases 
(liver, retroperitoneal lymph nodes, lungs, bones, and 
brain), with rates of 20.2% versus 13.9% for the chemo-
therapy associated with radiation therapy and radiother-
apy alone, respectively, the difference was not significant 
(ARR= -0.063 with 95% CI: -0.180-0.054)40(A). There 
was no significant difference in survival of patients when 
comparing the two regimens (82.1% versus 84.7% for 
chemotherapy associated with radiotherapy and radio-
therapy alone, respectively, with ARR= -0.026 and 95% 
CI: -0.143-0.091)40(A).
RECOMMENDATION
The use of chemotherapy associated with radiotherapy in 
patients with high-grade endometrial carcinoma shows no 
reduction in rates of distant metastases and does not im-
prove overall survival.
7. IS THE USE OF CHEMOTHERAPY IN PATIENTS WITH 
ADVANCED ENDOMETRIAL CARCINOMA (STAGES III OR IV) 
ASSOCIATED WITH HIGHER OVERALL SURVIVAL, WHEN 
COMPARED TO RADIOTHERAPY ALONE?
Patients with advanced-stage endometrial carcinoma 
are rarely candidates for surgery. Stages III and IV endo-
metrial carcinoma presents as a heterogeneous group of 
tumors with varied prognosis, and individualization 
of treatment should be performed according to the disease 
extension41(B). Considering the high recurrence rates, in 
recent years total abdominal radiotherapy has been used;, 
for the treatment of extra-abdominal metastases, chemo-
therapy is indicated, with substantial improvements in 
overall survival rates of these patients but without neglect-
ing the cytotoxicity of chemotherapy42,43(A)44-46(B).
In patients with stages III or IV endometrial carci-
noma, initially subjected to cytoreductive surgery, with 
residual disease < 2.0 cm, and subsequently treated with 
total abdominal radiotherapy and pelvic reinforcement 
(30 Gy + reinforcement of 15 Gy) or with chemotherapy 
consisting of eight cycles of 60 mg/m2 of doxorubicin com-
bined with 50 mg/m2 of cisplatin, and a follow-up period 
of 74 months, there was significant increase in overall sur-
vival with the chemotherapy regimen (51% versus 38% 
for chemotherapy and radiotherapy, respectively, with 
ARR= -0.129 and 95%CI: -0.226 to -0.032)47(A).
Regarding adverse events, it is noteworthy that they, 
particularly hematological grades 3 and 4, gastrointestinal, 
cardiac, and neurological, are significantly more frequent 
with the use of chemotherapy47(A).
RECOMMENDATION
Patients with advanced-stage endometrial carcinoma 
(stages III or IV) show significant improvement in overall 
survival with the use of chemotherapy, but it is associated 
with a higher frequency of adverse events. 
8. WHAT IS THE BEST FOLLOW-UP STRATEGY IN PATIENTS 
TREATED FOR ENDOMETRIAL CARCINOMA WHO ARE CLINICALLY 
DISEASE-FREE?
The concept of long-term surveillance of patients treated 
for endometrial carcinoma with curative intent is based on 
the premise that early detection results in decreased mor-
bimortality associated with recurrence. Currently, follow-
up protocols are highly variable, using different diagnostic 
tests and various intervals. Thus, there is no formal rec-
ommendation regarding the monitoring and follow-up of 
these patients48(D).
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The main factors associated with survival time and 
recurrence of disease are represented by tumor grade and 
histology, depth of myometrial invasion, metastasis to 
lymph nodes, and presence of extrauterine disease49(B). 
The anatomical locations of recurrences are roughly 
equivalent both locally (pelvic) and at distance (abdo-
men and thorax); the most common sites of involvement 
are the vaginal cuff, pelvis, and lungs50(A)51(B). Regard-
ing rescue rates by appropriate therapy in cases of recur-
rence, there are controversies, and some publications 
have shown values that vary from 10% to 38% 52(C)48(D).
When evaluating retrospective studies reporting 
strategies for the follow-up of patients receiving poten-
tially curative treatment for endometrial carcinoma and 
who were clinically free of disease at the beginning of 
the evaluation, it was observed that most recurrences 
(recurrence rate of 13% among the studies) occurred on 
average in the first three years after treatment completion 
(ranging from 2 to 3.5 years of follow-up) and of these, 
77% were symptomatic53(A)54-58(B).
Regarding follow-up intervals, it was observed that 
these were variable between studies (ranging from 12 to 
32 consultations during a five-year follow-up period), 
and the tests performed to detect recurrences consisted 
mainly of physical examination, vaginal cytology, and 
chest radiography. The use of ultrasound, computed 
tomography (CT), and CA 125 measurement were 
not used, in general, as part of the routine follow-up 
studies54,56,59(B).
The detection of asymptomatic recurrence in the 
studies ranged from 5% to 33% for patients undergoing 
physical examination, 0% to 4% with vaginal cytology, 
0% to 14% with chest X-ray, 4% to 13% with abdominal 
ultrasonography, 5% to 21% with abdominal/pelvic CT, 
and 15% in patients selected for CA 125 measurement, 
and there is no clear evidence that the request for such 
examination reduces mortality in recurrent disease60(A).
The request for mammography and Pap smear collec-
tion should follow the guidelines of breast and cervical 
cancer screening. For patients at risk for colon cancer, a 
colonoscopy must be requested and the need for endos-
copy should be evaluated.  
RECOMMENDATION
There is no evidence that follow-up examinations in as-
ymptomatic women with normal test results reduce mor-
tality. Periodic consultations up to a period of three years 
of follow-up (every three or four months) are recom-
mended, with anamnesis aimed at test requests accord-
ing to symptoms and abnormal test results. After this, the 
consultation period may be twice a year for five years, 
and then annually60(A).
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